Addiction Treatment Market, by Drug Type (Opioid Addiction, Alcohol Addiction, Nicotine Replacement Therapies, and Non-Nicotine Medication), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook

Addiction Treatment Market, by Drug Type (Opioid Addiction, Alcohol Addiction, Nicotine Replacement Therapies, and Non-Nicotine Medication), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Addiction is a chronic condition which gives rise to psychological and physical damage. People who suffer from an addiction have an uncontrollable desire and lack of resistance to use lethal substances or to involve in harmful activities in spite of knowing their negative effects on their lives. Indications of addiction differ from person to person. Some have serious symptoms, such as inability to stop using addictive substance, increased tolerance for such addictive substance, lack of control as well as physical and emotional withdrawal. Risk of developing an addiction can be minimized by avoiding illegal drugs and immediately looking for counselling in case of any mental health disorder. A person suffering from an addictive disorder needs access to treatment. In many cases treatment may continue for the rest of their life. As per the patient’s need, treatment plans for addictive disorders will frequently modify. Treatment options depend on various factors such as the type of addictive disorder, the duration and danger of use, and its impact on the individual.
According to the National Survey on Drug Use and Health, in the U.S., approximately 8.1 percent of the population need or undergo treatment for drug addiction.
Market Dynamics
The rising prevalence of addicted population, expanding drug product pipeline, and active involvement of generic manufacturers to provide cheaper drugs are the major factors that are expected to drive the growth of the global addiction treatment market over the forecast period.
For instance, manufacturers such as Insys Therapeutics (innovative Buprenorphine / Naloxone sublingual spray), BioCorRx, Inc. (Naltrexone Implant (BICX102)) have novel products in their pipeline for opioid and alcohol addiction treatment.
Key features of the study:
This report provides an in-depth analysis of the global addiction treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global addiction treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Alkremes Plc., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Titan Pharmaceuticals, Inc., Pfizer, Inc., GlaxoSmithKline plc., Johnson & Johnson, Perrigo Company plc., Cipla Limited, Hikma Pharmaceuticals Plc., Dr. Reddy’s Laboratories Limited, Indivior Inc., and Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global addiction treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global addiction treatment market
Detailed Segmentation:
Global Addiction Treatment Market, By Drug Type:
Opioid Addiction
Methadone
Buprenorphine
Naltrexone
Alcohol Addiction
Acamprosate
Disulfiram
Naltrexone
Others
Nicotine Replacement Therapies
Nicotine Gums
Nicotine Patches
Nicotine Lozenges
Nicotine Spray
Nicotine Inhaler
Nicotine Sublingual Tablets
Non-Nicotine Medication
Varenicline
Bupropion (Zyban)

Global Addiction Treatment Market, By Region:
North America
By Drug Type
Opioid Addiction
Methadone
Buprenorphine
Naltrexone
Alcohol Addiction
Acamprosate
Disulfiram
Naltrexone
Others
Nicotine Replacement Therapies
Nicotine Gums
Nicotine Patches
Nicotine Lozenges
Nicotine Spray
Nicotine Inhaler
Nicotine Sublingual Tablets
Non-Nicotine Medication
Varenicline
Bupropion (Zyban)

By Country
U.S.
Canada
Latin America
By Drug Type
Opioid Addiction
Methadone
Buprenorphine
Naltrexone
Alcohol Addiction
Acamprosate
Disulfiram
Naltrexone
Others
Nicotine Replacement Therapies
Nicotine Gums
Nicotine Patches
Nicotine Lozenges
Nicotine Spray
Nicotine Inhaler
Nicotine Sublingual Tablets
Non-Nicotine Medication
Varenicline
Bupropion (Zyban)

By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type
Opioid Addiction
Methadone
Buprenorphine
Naltrexone
Alcohol Addiction
Acamprosate
Disulfiram
Naltrexone
Others
Nicotine Replacement Therapies
Nicotine Gums
Nicotine Patches
Nicotine Lozenges
Nicotine Spray
Nicotine Inhaler
Nicotine Sublingual Tablets
Non-Nicotine Medication
Varenicline
Bupropion (Zyban)

By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type
Opioid Addiction
Methadone
Buprenorphine
Naltrexone
Alcohol Addiction
Acamprosate
Disulfiram
Naltrexone
Others
Nicotine Replacement Therapies
Nicotine Gums
Nicotine Patches
Nicotine Lozenges
Nicotine Spray
Nicotine Inhaler
Nicotine Sublingual Tablets
Non-Nicotine Medication
Varenicline
Bupropion (Zyban)
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type
Opioid Addiction
Methadone
Buprenorphine
Naltrexone
Alcohol Addiction
Acamprosate
Disulfiram
Naltrexone
Others
Nicotine Replacement Therapies
Nicotine Gums
Nicotine Patches
Nicotine Lozenges
Nicotine Spray
Nicotine Inhaler
Nicotine Sublingual Tablets
Non-Nicotine Medication
Varenicline
Bupropion (Zyban)

By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Type
Opioid Addiction
Methadone
Buprenorphine
Naltrexone
Alcohol Addiction
Acamprosate
Disulfiram
Naltrexone
Others
Nicotine Replacement Therapies
Nicotine Gums
Nicotine Patches
Nicotine Lozenges
Nicotine Spray
Nicotine Inhaler
Nicotine Sublingual Tablets
Non-Nicotine Medication
Varenicline
Bupropion (Zyban)

By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Alkremes Plc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Teva Pharmaceutical Industries Ltd.
Glenmark Pharmaceuticals
Titan Pharmaceuticals, Inc.
Pfizer, Inc.
GlaxoSmithKline plc.
Johnson & Johnson
Perrigo Company plc.
Cipla Limited
Hikma Pharmaceuticals Plc.
Dr. Reddy’s Laboratories Limited
Indivior Inc.
Mylan N.V.
“*” marked represents similar segmentation in other categories in the respective section.